Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0L9NX
|
|||
Former ID |
DCL000974
|
|||
Drug Name |
Satavaptan
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Acute and chronic heart failure [ICD-11: BD1Z; ICD-10: I50, I50.9; ICD-9: 428] | Phase 3 | [1], [2] | |
Company |
Sanofi-Aventis
|
|||
Structure |
Download2D MOL |
|||
Formula |
C33H45N3O8S
|
|||
Canonical SMILES |
CCOC1=CC2=C(C=C1)N(C(=O)C23CCC(CC3)OCCN4CCOCC4)S(=O)(=O)C5=C(C=C(C=C5)C(=O)NC(C)(C)C)OC
|
|||
InChI |
1S/C33H45N3O8S/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24H,6,11-20H2,1-5H3,(H,34,37)
|
|||
InChIKey |
QKXJWFOKVQWEDZ-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 185913-78-4
|
|||
PubChem Compound ID | ||||
PubChem Substance ID | ||||
SuperDrug ATC ID |
A08AA03
|
|||
SuperDrug CAS ID |
cas=000090846
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Vasopressin V2 receptor (V2R) | Target Info | Antagonist | [2], [3], [4] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Vasopressin-regulated water reabsorption | ||||
Pathwhiz Pathway | Vasopressin Regulation of Water Homeostasis | |||
Pathway Interaction Database | Arf6 trafficking events | |||
Reactome | Vasopressin-like receptors | |||
G alpha (s) signalling events | ||||
Vasopressin regulates renal water homeostasis via Aquaporins | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Regulation of Water Balance by Renal Aquaporins | ||||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2199). | |||
REF 2 | Post-translational import of protein into the endoplasmic reticulum of a trypanosome: an in vitro system for discovery of anti-trypanosomal chemical entities. Biochem J. 2009 Apr 15;419(2):507-17. | |||
REF 3 | Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes. 1999;107(3):157-65. | |||
REF 4 | Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest. 2000 Jul;106(1):107-16. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.